8-K filing — BeyondSpring Inc. (BYSI)
Filed: 2026-10-06 AccNo: 0001171843-26-006465 Size: 362 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 9.01: Financial Statements and Exhibits
Stocks · News reference
BeyondSpring shares are trading lower. The company announced the FDA has granted Fast Track designation to Plinabulin and docetaxel for advanced non-small cell lung cancer.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BeyondSpring Says FDA Granted Fast Track To Plinabulin Plus Docetaxel In Lung Cancer; Agrees To Sell Majority Of China Unit To Biolin, Which Will Fund China Phase 3 Enrollment
BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year.